TICKERNERD
Menu
SCYXSCYXHealthcare · Drug Manufacturers - Specialty & Generic

SCYX Stock Forecast: SCYNEXIS, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$3.95
+3.95% on the day

The 3 Wall Street analysts covering SCYNEXIS, Inc. hold a median 12-month price target of $33 — +735.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 28 Oct 2026 — in the lower half.

Market cap
$37.8M
Ticker Nerd rank
41/ 100
Median analyst target
$33
Analysts covering
3
Revenue$235K−82.8% y/y
Operating income−$7.8M
Net income$7.4M
Free cash flow−$14.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.4%
1M
−14.5%
YTD
−21.9%
1Y
−30.9%
From 52W high
−55.5%
From 52W low
+10.6%
$3.57
$8.88
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SCYX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SCYNEXIS, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
41/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Size
82
Volatility
57
Revisions
54
Quality
48
Momentum
40
Issuance
39
Value
15
Accruals
15

Growth (87): Sales and profits are climbing, and climbing faster than before.

Accruals (15): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SCYX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SCYX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00$40.00$50.00Jan 26Apr 26Jul 26Oct 26SCYXHigh $44Median $33Low $32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $32Median $33High $44

The green dot is the last close — the median target sits +735.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026GuggenheimMaintainsBuy$24 → $33
28 Oct 2025GuggenheimMaintainsBuy$4.00 → $3.00
28 Oct 2025GuggenheimMaintainsBuy—
1 Apr 2024Cantor FitzgeraldReiteratesOverweight—
15 Aug 2023Cantor FitzgeraldReiteratesOverweight—
3 Apr 2023GuggenheimMaintainsBuy—
3 Apr 2023Ladenburg ThalmannReiteratesBuy—
1 Mar 2023GuggenheimInitiatesBuy—
21 Oct 2022Brookline CapitalAssumesBuy$8.00
13 May 2022HC Wainwright & Co.MaintainsBuy—
31 Mar 2022HC Wainwright & Co.MaintainsBuy—
7 June 2021Aegis CapitalMaintainsBuy—
12 Apr 2021Aegis CapitalMaintainsBuy—
22 Jan 2021GuggenheimInitiatesBuy—
6 Jan 2021Cantor FitzgeraldInitiatesOverweight—
28 Dec 2020HC Wainwright & Co.ReiteratesBuy—
25 Nov 2020Aegis CapitalMaintainsBuy—
25 Nov 2020Brean CapitalInitiatesBuy—
25 Nov 2020Canaccord GenuityInitiatesBuy—
25 Nov 2020GuggenheimInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SCYX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SCYX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, SCYNEXIS, Inc. returned −30.9% against +13.6% for the S&P 500, dividends included.

SCYX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26SCYXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SCYX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

SCYNEXIS, Inc. (SCYX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.9×

Cheaper than 71% of US stocks

Price / sales
2.0×

Cheaper than 52% of US stocks

Price / book
0.6×

Cheaper than 81% of US stocks

EV / EBITDA
1.0×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
−82.8%

Higher than 3% of US stocks

Earnings growth (YoY)
−82.8%

Higher than 5% of US stocks

Gross margin
—
Operating margin
−3308.5%

Higher than 3% of US stocks

Net margin
−53.3%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−18.4%

Higher than 32% of US stocks

Return on assets
−20.8%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SCYNEXIS, Inc. (SCYX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SCYNEXIS, Inc. has a market value of $37.8M and an enterprise value of −$14.3M.

  • Revenue in the twelve months to 30 June 2026: $19.2M. The latest quarter shrank 82.8% year on year.

  • Net income over the same four quarters: −$10.2M, a −53.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$13.3M.

  • Shares outstanding: 9.9M.

  • Trailing P/E: 0.9×; forward P/E: −1.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • SCYNEXIS, Inc. employs 18 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

SCYX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
SCYXSCYNEXIS, Inc.$37.8M41
ZYBTZhengye Biotechnology Holding Ltd.$42.2M49
IXHLIncannex Healthcare, Inc.$32.4M24
RMTIRockwell Medical, Inc.$28.9M56
CTORCitius Oncology, Inc.$53.6M40
TLPHTalphera, Inc.$54.6M37
CPHIChina Pharma Holdings, Inc.$26.7M41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SCYNEXIS, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SCYX news & analysis

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

GlobeNewsWire · 22 Oct 2026positive

SCYNEXIS announced topline results from a Phase 1 single- and multiple-ascending-dose trial of intravenous SCY-247, its second-generation triterpenoid antifungal candidate. The company is developing SCY-247 in oral and IV formulations to treat and prevent invasive fungal infections.

Why it matters — The Phase 1 update concerns an investigational candidate aimed at invasive fungal infections, including infections involving drug-resistant fungi.

SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek

GlobeNewsWire · 21 Oct 2026positive

SCYNEXIS said its SCY-247 antifungal candidate will be featured in an oral company pipeline presentation at IDWeek, held October 21–24, 2026. The candidate is being developed in oral and intravenous formulations for the treatment and prevention of invasive fungal infections.

Why it matters — The presentation puts SCY-247, including its development for drug-resistant fungal infections, in focus for SCYX watchers.

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

GlobeNewsWire · 6 Oct 2026positive

SCYNEXIS announced Phase 1 results for SCY-770, a direct AMPK activator being studied for autosomal dominant polycystic kidney disease. The drug was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated.

Why it matters — The results provide an update on SCY-770’s early-stage safety profile and development for ADPKD.

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

GlobeNewsWire · 28 Sept 2026positive

SCYNEXIS announced it has been awarded a contract by BARDA, part of the U.S. Department of Health and Human Services, providing up to $214 million in non-dilutive funding to advance development of SCY-247, the company's second-generation antifungal candidate.

Why it matters — A SCYX watcher would care because this contract provides substantial non-dilutive funding that supports the advancement of SCY-247 without requiring the company to raise additional capital.

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.

GlobeNewsWire · 22 Sept 2026positive

SCYNEXIS, Inc. announced the appointment of seasoned industry veteran Steven K. Burke, M.D., to the Company. The announcement was made on September 22, 2026, via press release.

Why it matters — Adding an experienced industry veteran to the leadership team could bring valuable expertise to SCYNEXIS as it works to advance innovative solutions for severe rare diseases.

FAQ

Frequently asked questions about SCYX stock

What is the SCYX stock price forecast for 2026-2027?

The 3 Wall Street analysts covering SCYNEXIS, Inc. have a median 12-month price target of $33, with estimates ranging from $32 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SCYX stock a buy right now?

Of the 3 analysts covering SCYNEXIS, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SCYNEXIS, Inc. 41 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SCYX?

As at 28 Oct 2026, SCYNEXIS, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

Will SCYX stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +735.4% from the last close, and Ticker Nerd's factor model ranks SCYNEXIS, Inc. 41 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SCYX stock forecast for 2030?

No analyst covering SCYNEXIS, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SCYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $44 over the next 12 months.

How has SCYX stock performed over the past year?

SCYNEXIS, Inc. returned -30.9% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SCYNEXIS, Inc. do?

SCYNEXIS, Inc. Common Stock represents the equity of SCYNEXIS, Inc., a biotechnology company focused on developing therapies for difficult-to-treat and drug-resistant fungal infections as well as certain severe rare diseases.

What is the latest news on SCYX?

The most recent item we track (GlobeNewsWire, 22 Oct 2026): "SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases". SCYNEXIS announced topline results from a Phase 1 single- and multiple-ascending-dose trial of intravenous SCY-247, its second-generation triterpenoid antifungal candidate. The company is developing SCY-247 in oral and IV formulations to treat and prevent invasive fungal infections.

Company

About SCYNEXIS, Inc.

SCYNEXIS, Inc. Common Stock represents the equity of SCYNEXIS, Inc., a biotechnology company focused on developing therapies for difficult-to-treat and drug-resistant fungal infections as well as certain severe rare diseases. The company markets BREXAFEMME for vulvovaginal candidiasis and recurrent vulvovaginal candidiasis, while also advancing investigational candidates such as ibrexafungerp and SCY-247 for broader antifungal and infectious disease applications. SCYNEXIS works across drug development, commercialization, and collaborative partnerships to support the treatment and prevention of serious infections with limited options. Headquartered in Jersey City, New Jersey, the company operates in the specialty pharmaceuticals segment of the healthcare market and serves as a focused biotechnology platform centered on anti-infective innovation.

CEO Dr. David Gonzalez Angulo M.D. · 18 employees · United States · https://www.scynexis.com